LDL-IN-3

LDL-IN-3 is an anti-atherosclerotic compound extracted from patent WO/2005/039596A1, example C25 and patent US 6133467, example 3.

Signaling Pathways >> Others >> Others

Research Areas >> Metabolic Disease

Research Areas >> Cardiovascular Disease

LDL-IN-3 is antioxidant which inhibits low density lipoprotein (LDL) lipid peroxidation and is useful as anti-atherosclerotic agents[1][2].

LDL-IN-3 decreases serum cholesterol, TBARS and the amount of aortic lesions (57 %) in comparison with control rabbits. LDL-IN-3 is found in very high concentrations in the serum (182.4 μg/mL) and livers (323 μg/mL)[1][2].

[1]. WO/2005/039596A1

[2]. US 6133467

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline